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Anemia is one of the most frequent complications and/or extraintestinal manifestations of
inflammatory bowel disease (IBD). Iron deficiency is the most important cause of anemia
in Crohn’s disease and ulcerative colitis patients. Iron deficiency even without anemia may
impact the quality of life of our IBD patients. In the last 10 years, the understanding of
the pathology of iron-deficiency anemia and “anemia of chronic diseases” has increased;
new diagnostic tools have been developed and new therapeutic strategies have been dis-
cussed. Hepcidin has been identified to be a central regulator of iron absorption from
the intestine and of iron plasma levels. Hepcidin is regulated by iron deficiency but also
as an acute phase protein by pro-inflammatory mediators such as interleukin-6. Innova-
tive diagnostic tools have not been introduced in clinical routine or are not available for
routine diagnostics. As iron substitution therapy is easy these days with a preference for
intravenous substitution, the impact of differential diagnosis of anemia in IBD patients is
underestimated.
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ANEMIA IS A FREQUENT PROBLEM IN IBD PATIENTS
Anemia represents the most common systemic complication
and/or extraintestinal manifestation in inflammatory bowel dis-
ease (IBD) (1, 2). A recent systematic review of relevant manu-
scripts published between 2007 and 2012 reported a prevalence of
anemia in patients with Crohn’s disease of 27% (95% confidence
interval, 19–35) and of 21% (95% confidence interval, 15–27) in
patients with ulcerative colitis (2). More than half of the anemic
patients (57%) were found to be iron deficient (2). Others report
a prevalence of anemia in IBD patients ranging between 6.2 and
73.3% (3).
In IBD outpatients, the frequency of anemia appears to be
lower (16%) as compared to hospitalized patients (68%) (3). Ane-
mia prevalence in hospitalized IBD patients ranges from 44% as
reported by Hoffbrand et al. (4) up to 74% as found by Wer-
lin and Grand (5). However, the latter numbers were reported in
older studies from the 60s and 70s. The prevalence has decreased
as obvious from newer investigations and meta-analyses, but the
overall progress we have made in improving treatment of anemia
and outcome is surprisingly small.
Some studies have found a correlation between high Crohn’s
disease activity index (CDAI) and anemia; however, this is not sur-
prising as the hematocrit value is one parameter for the calculation
of the CDAI. Therefore, CDAI and hematocrit/hemoglobin levels
are no independent parameters and should not be analyzed as
independent variables. On the other hand, it has been repeatedly
described that anemia as well as iron deficiency significantly impair
Abbreviations: CD, Crohn’s disease; IBD, inflammatory bowel disease; IL, inter-
leukin; NF-κB, nuclear factor κB; UC, ulcerative colitis.
the quality of life in patients with chronic intestinal inflammation
(6). In the FERGIcor study, a randomized controlled trial on
ferric carboxymaltose for iron-deficiency anemia (IDA) in IBD
patients disease-related (IBDQ) and mental quality of life (SF-
36) improved by iron supplementation during the 12-week-study
period (7). Similar findings on the quality of life are reported from
other iron supplementation studies (8, 9). On the other hand,
being anemic or iron deficient was not associated with increased
fatigue in a Scandinavian cohort (10).
A successful therapy of anemia may even improve the quality of
life better than the therapy of disease activity (anti-inflammatory
therapy) (6). Further, anemia was even found to be among the
most frequent comorbid conditions associated with death in IBD
patients (11). However, in those patients, it may simply reflect the
severity of the underlying IBD.
In the last decades, the incidence of anemia in IBD patients
has been reported to decrease (3). This observation is probably
related to improvements in treatment of these diseases or in iron
supplementation. On the other hand, our recent study indicated
that treating gastroenterologists may still accept the concept of
“asymptomatic anemia,” claiming that patients would adapt to low
hemoglobin levels if anemia developed slowly as this is typically
the case in IBD (12).
Several reasons for anemia in IBD patients exist. Iron deficiency
(Figure 1), vitamin B12 deficiency, and anemia of chronic diseases
are certainly the most important. Iron deficiency is found fre-
quently in IBD patients and ranges from 36 to 90% with a mean
prevalence of 45% (3).
When we looked into patient data of a cross-sectional cohort
in Switzerland (the Swiss IBD Cohort Study), we found ane-
mia in 12.9% of IBD patients in private practice, and 28.8% of
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FIGURE 1 | Distribution of iron in the human body (70 kg). Less than 10%
of the daily iron uptake of around 20 mg is absorbed by the intestinal mucosa.
The transferrin bound iron pool in the plasma consists of about only 3 mg in
total. Around 1000 mg are bound to ferritin and hemosiderin as iron storage in
the liver. One hundred to hundred and thirty milligrams are found in other
tissues [bound to myoglobin (Mb) or to enzymes]. Erythrocytes (Ec) contain
about 2000 mg iron in total bound to hemoglobin (Hb). Eighty milligrams are
found in the reticulo-endothelial system (RES) in which senescent
erythrocytes are degraded. From the RES, iron is released into the serum
contributing to the pool bound to transferrin. Around 1 mg of iron is
physiologically lost each day contributing to a balance of iron metabolism and
making a higher uptake in the intestine normally unnecessary.
IBD patients in tertiary centers (12). Whereas this difference was
statistically significant, the frequency of iron deficiency was not
different between patients treated in university hospitals from
patients in private practice (12). As expected in this cohort-
based study, a higher CDAI was correlated with lower hemoglobin
levels (12).
IRON DEFICIENCY IN IBD PATIENTS
Iron deficiency still has a high prevalence in patients with
IBD, which is not always paid sufficient attention to (13). In a
population-based cohort of 279 patients (183 Crohn’s disease, 90
ulcerative colitis, and 6 indeterminate colitis) in Germany, Ott and
coworkers found an IDA in 26 of 68 patients with anemia (38.2%),
but only 9 patients received subsequent iron therapy (13). The
numbers did not change a lot after 1 year as still 27 patients were
identified to have an IDA, however, 71.4% of them were treated
(13). 54.3% did not receive iron substitution despite IDA (13).
This indicates that there is still a high prevalence of iron deficiency
in the IBD population, which does not change a lot after the diag-
nosis is established and that frequently iron deficiency is treated
insufficiently.
Two major reasons for iron deficiency associated with IBD have
to be considered. One is an impaired uptake (Figure 1), e.g., due
to functionally disturbed absorption caused by inflammation of
the ileum. An impaired absorption also may occur in patients
with severe ulcerative colitis. If patients have more than 20 bowel
movements per day and report that food appears in the rectum
30 min after uptake, it is easy to imagine that a sufficient absorp-
tion time in the small bowel is not present (14, 15). This is also
indicated by the fact that patients with severe ulcerative colitis
may have reduced serum protein and albumin levels indicating a
malabsorption. An additional mechanism that antagonizes iron
absorption in the gut is discussed below. The second major reason
for an iron deficiency in IBD certainly is the continuous blood loss
in active colitis or ileitis associated with a depletion of iron and
iron stores (Figure 1).
As iron is an essential component of heme and hemoglobin, it
is obvious that malabsorption of iron or continuous loss of iron
may restrict iron delivery to erythrocyte precursors (Figure 1) and
subsequently limits erythropoiesis (16, 17).
Iron deficiency may already impact the quality of life with-
out anemia (16, 18–20). This may be partially caused by non-
hematological effects of iron-deficiency (21, 22); however, the
impact, for example, on myoglobin function is somewhat con-
troversial.
In the past, the diagnosis of IDA was based on traditional bio-
chemical markers such as serum iron, transferrin saturation (TfS),
and ferritin (23–25). Better parameters to identify iron deficiency
such as soluble transferrin receptor (sTfR) are not applied widely
(26). If the “traditional” markers appeared to be in a normal range
and there still was an anemic blood count in IBD patients, this
was attributed to “anemia of chronic disease” (24, 27–29). Con-
secutively, this was a diagnosis of exclusion and no positive criteria
were used.
In the last 10 years, the understanding of the pathophysiol-
ogy of anemia has made huge progress and this should change
our diagnostic procedures in IBD patients and finally modify
treatment strategies. A very important regulator of iron home-
ostasis, centrally involved in iron absorption is hepcidin (30). It
not only determines the rates of absorption but also influences
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plasma iron levels and iron distribution (30). Hepcidin is pro-
duced and secreted mainly by hepatocytes, and to a lesser extent
by macrophages and adipocytes (30). To fully understand the rea-
sons for iron deficiency in IBD patients, the function of hepcidin
has to be addressed.
ROLE OF HEPCIDIN FOR IRONMETABOLISM IN IBD PATIENTS
The protein hepcidin was first described in 2000 as a member of
the anti-microbial protein family of defensins (31, 32). Besides
the site of synthesis (“hep”) and the anti-microbial properties
(“cide”) that occur in the name hepcidin has important further
functions (30, 33, 34). Under physiologic conditions, hepcidin
inhibits iron flow into plasma from macrophages that have taken
up and degraded senescent erythrocytes as well as their hemo-
globin, and also from small intestinal epithelial cells involved in
the absorption of dietary iron (35–38) (Figure 2A). This iron
release from cytoplasmic stores is prevented by binding of hep-
cidin to the iron exporter protein ferroportin (39–41) (Figure 2B).
Ferroportin is internalized and degraded upon hepcidin activity
(Figure 2B). This mechanism of ferroportin degradation requires
ubiquitination that is induced or triggered by hepcidin (39, 40).
As ferroportin is the most important protein to liberate iron from
cytoplasmic stores, a degradation of ferroportin must reduce the
iron available for erythropoiesis (34, 42–44) (Figure 2B). In small
intestinal epithelial cells, this would mean that iron is “locked” in
the cytoplasmic stores without a chance to enter the plasma and
subsequently circulation where it finally may arrive in the bone
marrow for erythropoiesis (Figure 2B). The retention of iron in
the small intestinal epithelial cells also means a loss of this iron
pool as the enterocytes will be exfoliated during their normal life
cycle within 5 days finally leading to loss of this “trapped” iron for
the body.
Hepcidin synthesis is regulated by iron and erythropoietic
activity (45, 46) (Figure 2A). Hepcidin expression is down-
regulated in anemia with concomitant iron deficiency (46). Thus,
ferroportin is not internalized from the cell membrane and iron
can be transported from stores to the plasma to provide heme
synthesis and erythropoiesis with more iron (Figure 2B). Iron defi-
ciency is associated with reduced bone morphogenetic protein-6
expression and impaired SMAD1/5/8 phosphorylation, which are
key events for hepcidin transcription and expression (45, 46). On
the other hand during anemia of chronic diseases (without signifi-
cant iron deficiency), hepcidin expression is even increased, which
may explain why iron is “trapped” intracellularly under these con-
ditions (46) (Figure 2A). As obvious, sensing of iron levels and an
early detection of an iron deficiency is of crucial importance.
Plasma iron levels are sensed and “measured” by two transfer-
rin receptors (TfR1 and TfR2) (47–49). Both receptors transmit
the information on plasma transferrin levels to intracellular sig-
naling pathways that among other cellular reactions also regulate
hepcidin synthesis (50, 51). High plasma iron levels and high iron
stores or even “iron overload” will stimulate hepcidin synthesis,
which then inhibits iron absorption from the intestinal lumen.
In contrast, iron deficiency and increased erythropoietic activ-
ity suppress hepcidin transcription and translation, decreasing
its synthesis. Subsequently, in anemic IBD patients in remis-
sion with iron-deficiency, low hepcidin levels have been reported
FIGURE 2 | (A) Regulation of iron absorption by hepcidin. Hepcidin
synthesis is increased upon iron or inflammation in the liver. Inflammation
in the gut will lead to increased IL-6 serum levels followed by higher
amounts of hepcidin in the circulation. Hepcidin then decreases iron
absorption in the gut and iron recycling from the RES leading to reduced
iron availability for hem formation in the bone marrow. (B) On a molecular
level in the enterocytes – the absorptive cells of the intestinal brush border
membrane – hepcidin prevents iron release from enterocyte cytoplasmic
stores by binding to the iron exporter protein ferroportin. This is followed by
ferroportin internalization and degradation. Thus, iron is trapped
intracellulary without being able to reach the blood stream (DMT1, divalent
metal transporter 1 is a protein by the SLC11A2 gene (solute carrier family
11, member 2). DMT1 is a metal ion transporter protein that binds a variety
of divalent metals including copper (Cu2+) and zinc (Zn2+) but is best known
for transporting ferrous iron (Fe2+).
(30, 52–57). The low hepcidin normally would allow increased
absorption of dietary iron and release of iron from stores, which
may not always be possible in IBD patients. Why do patients with
IBD sometimes show increased hepcidin levels despite an iron
deficiency?
In IBD (similar to other chronic inflammatory disease or infec-
tions), it can be assumed that inflammation increases hepcidin
expression and synthesis as hepcidin also is an “acute phase pro-
tein” (38, 45). This induction of hepcidin protein synthesis is
at least partially mediated by interleukin-6 via its receptor and
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subsequent intracellular signal transduction via signal transducer
and activator of transcription-3 (STAT3) (45, 52, 53, 58–60). Other
cytokine-mediated pathways also may play a role. Increased hep-
cidin levels in patients with IBD and other inflammatory diseases
cause the retention of iron in macrophages and enterocytes, lead-
ing to hypoferremia and iron-restricted erythropoiesis (53). In
a recent study by Basseri and coworkers, a positive correlation
between serum hepcidin and IL-6 levels in IBD patients was
confirmed (53). The authors further detected a strong negative
correlation between serum hepcidin concentrations and hemoglo-
bin levels (p= 0.029) (53). The authors conclude that anemia of
chronic diseases is associated with high serum IL-6 and hepcidin
levels, which supports the hypothesis that IL-6-driven hepcidin
production mediates anemia in patients with IBD (53). With this
in mind, the new therapeutic anti-IL-6 strategies tested in clinical
trials in patients with Crohn’s disease may be of special interest
also for anemia of chronic diseases in IBD.
In contrast, when serum hepcidin levels were investigated from
247 IBD patients (130 CD and 117 UC) from the Swiss Inflam-
matory Bowel Disease Cohort Study (SIBDCS), we found that
independent of inflammatory activity, all patients with decreased
ferritin had significantly lower hepcidin levels (55). Further, a
significant correlation between serum ferritin levels and serum
hepcidin was found (55). In this cohort by applying a backward
multi-linear stepwise regression analysis only ferritin, but none of
the inflammatory markers correlated significantly with hepcidin
concentration suggesting that iron deficiency was the key trigger
for hepcidin regulation (55). Thus, depending on the IBD popu-
lation, an acute phase reaction may play a role or not for hepcidin
regulation, iron deficiency, and subsequent anemia.
SHOULD WE CHANGE OUR DIAGNOSTIC ROUTINE WITH
RESPECT TO IRON DEFICIENCY AND ANEMIA IN IBD
PATIENTS?
As mentioned, the laboratory evaluation of anemia and iron
deficiency in IBD patients has traditionally been based on low
serum iron, low TfS, and low ferritin. However, those commonly
used laboratory tests as well as total iron-binding capacity and
mean corpuscular volume provide only limited diagnostic value
in patients with chronic active IBD or in patients presenting with
acute flares of the IBD in whom we do not have recent determi-
nations of the discussed parameters. The acute phase reaction will
definitely change the ferritin values determined. Inflammation can
mimic some aspects of iron deficiency by impairing the utiliza-
tion of existing iron stores for red cell production as explained in
detail above. The pathophysiological mechanism responsible for
the reduced availability of iron from its cytoplasmic stores may be
caused by cytokine stimulated hepcidin expression and subsequent
ferroportin degradation.
Serum ferritin has the potential to differentiate true iron defi-
ciency from inflammatory iron sequestration. However, ferritin
determination has its limitations as it is an acute phase protein
and may show false high levels in patients with low iron stores due
to an acute flare of the underlying IBD (61). Both inflammation
and intracellular iron accumulation can stimulate the production
of ferritin. Therefore, interpretation of serum ferritin in patients
with inflammation is tricky (55, 62, 63).
The differentiation among absolute iron deficiency, func-
tional iron deficiency, and iron-sequestration syndromes (lead-
ing to “anemia of chronic diseases”) is important for patient
management (61).
Increased serum levels of sTfR protein have been reported to
be a good indicator of iron deficiency (24, 26, 48, 61, 63–65). sTfR
is released in proportion to the expansion of erythropoiesis in
the bone marrow and is not regulated in its expression or secre-
tion by inflammation (24, 26, 63, 66). However, this assay has
not made it into clinical routine as it was found that it only can
provide a specificity of 84% and a positive predictive value of
only 58% in a population with diagnostically difficult situations
(67). Several indices have been calculated and evaluated for their
diagnostic accuracy, such as the combination of ferritin and sTfR
(sTfR/log ferritin) (68–70). However, still diagnostic sensitivity
and specificity are not completely satisfactory when inflammatory
conditions are present as in IBD patients.
Recent flow cytometry-based assays seem to improve the diag-
nostic repertoire. The flow cytometric analysis of reticulocytes
allows determination of reticulocyte hemoglobin (CHr) content
or percentage of hypochromic reticulocytes (71). This may be
more sensitive than the determination of erythrocyte hemoglobin
content or percentage of hypochromic erythrocytes (hypoE) (72).
The CHr is sufficiently sensitive to pick up iron-deficient erythro-
poiesis even in iron-replete volunteers receiving erythropoietin
(73). It has been suggested that those reticulocyte indices may
allow for real-time evaluation of iron-deficient erythropoiesis and
for rapid monitoring of the response to iron substitution therapy
(73). An algorithm to screen for iron deficiency including CHr
may even increase the accuracy of diagnosis (74).
For a sophisticated differential diagnosis, it may be helpful
to quantify hepcidin. Sensitive and accurate immunoassays for
human hepcidin have been developed; however, such an assay is
not available at many hospitals and even IBD focused care centers
even though normal values have been determined.
So what can be recommended as a diagnostic algorithm for
iron deficiency and anemia in IBD patients? A basic laboratory
screening test should include Hb, full blood counts including
reticulocytes, and the assessment of body iron stores including
serum ferritin and TfS (17). To evaluate the potential influence of
inflammation on serum ferritin C-reactive protein (CRP) as well
as calprotectin should be quantified. If anemia is detected further,
potential causes have to be evaluated including vitamin B12 and
folic acid levels. Haptoglobin, lactate dehydrogenase (LDH), and
serum creatinine are useful to exclude potential hemolysis or renal
disease, which may exist as extraintestinal manifestation of IBD or
as a side effect of medical therapy.
It has been recommended that also patients in clinical remis-
sion should be screened every 12 months, whereas patients with
active IBD should be screened for anemia every 3 months (17).
It has been emphasized that normal hemoglobin levels or normal
hematocrit do not exclude iron deficiency.
Reinisch and Munoz pointed to the fact that a normal hemo-
globin level with a mean corpuscular hemoglobin (MCH) in the
lower limit of normality (normal range: 28–35 pg) or an increased
red cell distribution width (RDW, normal range: 11–15) point to
mild iron deficiency without anemia (17, 75). RDW seems to be
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an independent marker of disease activity in IBD patients even
without anemia (76).
Iron deficiency in the absence of inflammation (normal CRP
and calprotectin) is characterized by low ferritin level <30 ng/mL
(1 ng/mL of serum ferritin corresponds to approximately of stored
iron). As ferritin is an acute phase protein, normal ferritin levels do
not exclude significant iron deficiency in patients with increased
CRP or significantly increased calprotectin. In these cases, TfS is
preferred and levels below 20% indicate iron deficiency (17).
Reticulocyte Hb content (CHr) may be able to discriminate IDA
from anemia of chronic disease (ACD. CHr is reported to have a
good sensitivity and specificity for diagnosing iron deficiency and
is less affected by inflammation (17, 75).
A low mean corpuscular Hb (MCH <27 pg), or a low reticu-
locyte Hb content (CHr <28 pg), rather than MCV <80 fL are
important markers for IDA. ACD should be suspected when
there is evidence of inflammation (as outlined above), anemia,
a low TfS (TfS <20%), and normal or increased serum ferritin
(>100 ng/ml).
Many patients may present with a combination of IDA and
ACD. In those patients, additional laboratory assays can be help-
ful: hepcidin levels correlate with ferritin and CRP and may replace
the ferritin index for confirmation of combined IDA and ACD
(hepcidin >4 nmol/L with CHr <28 pg (17, 77).
THERAPY OF IRON DEFICIENCY AND ANEMIA IN IBD
PATIENTS
Oral iron therapy is not well tolerated in many IBD patients. In
addition, intravenous iron preparations have proven higher effi-
cacy as compared to oral iron substitution therapy (78–82). The
effects of oral iron are difficult to investigate in IBD patients.
Therefore, it may be of some interest to look into animal mod-
els. Haller and coworkers provided evidence that iron may act as
oxidative mediator affecting inflammation at the intestinal surface
and inducing cell stress mechanisms (83). Histological analysis
of an iron-adequate fed mouse strain (approximately 0.54 mg of
iron/day) indeed induced ileal inflammation (83). The impact of
oral iron on oxidative stress and intestinal inflammation in the
animal model was at least in part mediated by the intestinal micro-
biota (84). An iron sulfate free diet in combination with systemic
iron repletion prevented the development of chronic ileitis in a
murine model of Crohn’s disease (84).
Thus, an intravenous therapy for iron substitution is gener-
ally preferred in IBD patients. This has been recommended in
international expert guidelines: Gasche and colleagues suggest that
“the preferred route of iron supplementation in IBD is intra-
venous, even though many patients will respond to oral iron.
Intravenous iron is more effective, better tolerated, and improves
the quality of life to a greater extent than oral iron supplements
(Grade A).” (85).
Whereas in mild iron deficiency and mild anemia, oral or intra-
venous iron substitution may be considered (with a clearly faster
and higher efficacy of the i.v. route) absolute indications for i.v.
iron substitution in IBD patients are severe anemia (hemoglo-
bin <10 g/dL) and disease activation upon, as well as intolerance,
or inappropriate response to oral iron (85). Furthermore, severe
IBD activity, concomitant therapy with an erythropoietic agent
(in severe anemia), or patient preference should be considered
(85). In general, dosing and administration intervals depend on
the compound.
There are sophisticated formulas to calculate the recommended
dosage or iron substitution with i.v. preparation. However, in
clinical practice, anemic IBD patients will rarely have a deficit
<1000 mg. To avoid iron overload, quantification of TfS may be
used. An increase of TfS above 50% may be a useful cut-off to
stop therapy and avoid iron overload, especially, as the risk of iron
overload can be considered to be very low in patients with active
IBD (85).
In severe cases of anemia, erythropoietin or even blood trans-
fusions may become necessary (85). However, these cases are rare
and may profit from the involvement of a specialist.
Hepcidin induced by pro-inflammatory mediators such as IL-6
in IBD patients may contribute to the lower efficacy of oral iron
substitution therapy in IBD patients (86, 87) leading to ACD (see
above).
HOWWILL THE NEW INSIGHTS IN IRON METABOLISM
IMPACT FUTURE THERAPY?
New therapies are under development especially for the treat-
ment of ACD. Some patients with ACD do not respond to
anti-inflammatory therapy and even erythropoietin therapy as
suggested in the respective guidelines. As in ACD, there is a func-
tional iron deficiency, i.v. iron supplementation in IBD patients
may be useful (34). However, iron overload should be avoided.
A new development for the treatment of resistant ACD is mon-
oclonal anti-hepcidin antibodies (34). A humanized anti-hepcidin
monoclonal antibody (mAb2.7) was shown to reverse iron restric-
tion and prevent anemia progression in animal models of anemia
(34). However, these antibodies may only work in combination
with erythropoietin.
As hepcidin is regulated by IL-6 available antibodies that already
have been approved for rheumatoid arthritis are presently tested
for their effect of hepcidin and ACD.
Another recent development is short interference RNA and
anti-sense oligonucleotides against hepcidin (34). The develop-
ment aims at directly downregulating expression of hepcidin on
the mRNA level. Amgen develops a short hairpin RNA (shRNA)
strategy against hepcidin, which already was tested in animal mod-
els (34). However, only very few anti-sense strategies have found
their way into clinical application.
Other agents under development are developed to bind or block
hepcidin to inactivate its function.
SUMMARY
New insights in the pathophysiology of iron deficiency and anemia
have been obtained in recent years. Iron deficiency and anemia are
important factors for the overall well-being of IBD patients and
frequently do not gain the attention they deserve. The diagnostic
algorithms have been changed by these new insights as outlined
in this overview. Here, parameters are mentioned that are avail-
able to most clinicians. Parameters that are very dependent on
local conditions and with limited specificity and sensitivity have
not been mentioned. The new insights into the pathophysiology
of IDA and ACD also slowly change our therapeutic approaches.
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An integrated care for IBD patients needs to include an up-to-
date management of iron deficiency and anemia. Future therapies
focused on hepcidin will most likely further improve treatment
options and outcome.
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